

June 2, 2016



Abeona Therapeutics to Present at 2016 BIO International Convention

Company Vice Chairman to Present on Tuesday, June 7th at 4 pm PT

NEW YORK, NY AND CLEVELAND, OH -- (Marketwired) -- 06/02/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Vice Chairman, Mark Ahn, Ph.D, will be presenting for the company at the BIO 2016 International Convention in San Francisco, CA, Tuesday, June 7th, 2016 at 4 pm PT.

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: BIO 2016 International Convention

Date: Tuesday, June, 7th, 2016

Time: 4 pm PT

Location: Moscone Center, San Francisco, CA

Room: Theatre 2

Webcast Link:

<http://www.veracast.com/webcasts/bio/internationalconvention2016/01233269686.cfm>

About the BIO 2016 International Convention:

The BIO 2016 International Convention is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO International Convention covers a wide spectrum of life science and application areas including drug discovery, bio manufacturing, genomics, biofuels, nanotechnology and cell therapy.

About Abeona :

Abeona Therapeutics Inc. delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV-NAGLU) and ABO-102 (AAV-SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). The company is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contact:

Andre'a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc
+1 (212)-786-6208
alucca@abeonatherapeutics.com

Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com

Source: Abeona Therapeutics